Safety, Tolerability and Efficacy of RGH-202 in Social Anxiety Disorder (STAGE)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07931703. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The reason for this trial is to see if the investigational product, called RGH-202, is safe and well tolerated, and can help people with social anxiety disorder. The main questions this study aims to answer are: * Is RGH-202 safe and well tolerated in adults with social anxiety disorder? * Does RGH-202 reduce symptoms of social anxiety disorder compared with placebo? RGH-202 will be compared with a placebo (a product that does not contain any active ingredients) to determine whether the investigational medicine may be an effective treatment for SAD. Participants will have an equal chance of receiving RGH-202 or the placebo taken for 6 weeks. Participants will attend regular clinic visits for safety assessments, study evaluations and complete questionnaires related to their social anxiety symptoms.
Study identification
- NCT ID
- NCT07931703
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 156 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2026 (Estimated)
- Primary completion
- Feb 13, 2028 (Estimated)
- Completion
- Feb 13, 2028 (Estimated)
- Last update posted
- Nov 12, 2026
2026 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Leading Edge Research LA, LLC | Encino | California | 91316 | — |
| Clinical Neuroscience Solutions, LLC | Jacksonville | Florida | 32256 | — |
| Clinical Neuroscience Solutions, LLC | Orlando | Florida | 32801 | — |
| Redbird Research LLC. | Las Vegas | Nevada | 89119 | — |
| Integrative Clinical Trials, LLC | Brooklyn | New York | 11229 | — |
| New Hope Clinical Research Inc. | Charlotte | North Carolina | 28211 | — |
| Clinical Neuroscience Solutions, LLC | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07931703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.